Approaches to Control Protein Aggregation during Bulk Production

Aggregation of Therapeutic Proteins

Volumn , Issue , 2010, Pages 257-299

  Narhi, Linda O ^a   Jiang, Yijia ^a   Deshpande, Rohini ^a   Kang, Sohye ^a   Shultz, Joseph ^a  

^a AMGEN INC   (United States)

Author keywords

Biological protein pharmaceutics class of therapeutics, high specificity, unique mechanism of action; Protein aggregation control approaches and bulk production; Protein folding, complex series of equilibria balancing unfolded, intermediate, native, and aggregated states

Indexed keywords

EID: 84886072770     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470769829.ch6     Document Type: Chapter

References (62)

1. FDA guidance concerning demonstration of comparability of human biological products, including therapeutic biotechnology-derived products, Center for Biologics Evaluation and Research and Center for Drug Evaluation and Research. April, 1996.
2. Carpenter JF, Randolph TW, Jiskoot WIM, Crommelin DJA, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg AS, Cherney B. 2008. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98 (4): 1201-1205.
3. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8: 501-507.
4. Swencki-Underwood B, Cunningham MR, Heavner GA, Blasie C, McCarthy SG, Dougherty T, Brigham-Burke M, Gunn GR, Goletz TJ, Snyder LA. 2006. Engineering human IL-18 with increased bioactivity and bioavailability. Cytokine 34 (1-2): 114-124.
5. Alber T. 1989. Mutational effects on protein stability. Annu Rev Biochem 58: 765-798.
6. Narhi LO, Stabinsky Y, Levitt M, Miller L, Sachdev R, Finley S, Park S, Kolvenbach C, Arakawa T, Zukowski M. 1991. Enhanced stability of subtilisin by three point mutations. Biotechnol Appl Biochem 13 (1): 12-24.
7. Bryan PN. 1992. Engineering dramatic increases in the stability of subtilisin. In Ahern TJ, Manning MC, eds., Stability of Protein Pharmaceuticals, Vol. B. New York: Plenum Press.
8. Hathway K, Gao S, Salmeron L, Chang J, Buko A. 2008. Assessment of manufacturability of protein drug candidates by ranking of antibody candidates based on accelerated stability studies. 236th ACS National Meeting, Division of Biochemical Technology, BIOT120, Philadelphia, PA, p. 52.
9. Ramachander R. 2008. Manufacturability assessments for early stage therapeutic candidate screenings. Presented at the IBC BPI Meeting, Anaheim, CA.
10. Jiang Y, Ramachander R, Wen J, Li C, Li J, Angell N, Bondarenco P, Narhi L. 2008. Manufacturability assessment for a successful therapeutic product. 236th ACS National Meeting, Division of Biochemical Technology, BIOT110, Philadelphia, PA, p. 49.
11. Wen J, Jiang Y, Narhi L. 2007. Applications of DSC for antibodies and Fc-conjugated proteins. Am Pharm Rev 10: 10-15.
12. Wen J, Jiang Y, Hymes K, Gong K, Narhi L. 2007. Using differential scanning calorimetry in understanding the correlation between thermal stability and protein stability. MicroCal Application Note.
13. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies-Application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 848 (1): 28-39.
14. Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. 1999. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol 309: 236-255.
15. Espinosa L, Schebor C, Nudelman NS, Chirife J. 2004. Stability of enzymes and proteins in dried glassy systems: Effect of simulated sunlight conditions. Biotechnol Prog 20 (4): 1220-1224.
16. Wurm FM. 2004. Production of recombinant proteins in cultivated mammalian cells. Nat Biotechnol 22 (11): 1393-1398.
17. Narhi LO, Arakawa T, Aoki KH, Elmore R, Rohde MF, Boone T, Strickland TW. 1991. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 266 (34): 23022-23026.
18. Wen J, Jiang Y, Narhi L. 2008. DSC for studying carbohydrate effect on antibodies. Am Pharm Rev 11 (6): 98-104.
19. Sol RJ, Greibenow K. 2009. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 98: 1223-1245.
20. Dissing-Olesen L, Thaysen-Andersen M, Meldgaard M, Hojrup P, Finsen B. 2008. The function of the human interferon-beta 1a glycan determined in vivo. J Pharmacol Exp Ther 326 (1): 338-347.
21. Makanji Y, Harrison CA, Stanton PG, Krishna R, Robertson DM. 2007. Inhibin A and B in vitro bioactivities are modified by their degrees of glycosylation and affinities to betaglycan. Endocrinology 148 (5): 2309-2316.
22. Shultz JE, Jiang Y, Wen J, Li C, Ramachander R, Stenson R, Pampel L, Gokarn Y, Narhi LO. 2008. Not all aggregates are the same: So, should they all be removed? Presented at the American Chemical Society National Meeting, Philadelphia, PA, August.
23. Paul S, Punam S, Chaudhuri TK. 2007. Chaperone-assisted refolding of Escherichia coli maltodextrin glycosidase. FEBS J 274 (22): 6000-6010.
24. Cromwell ME, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing. AAPS J 8 (3): E572-579.
25. Schroder M, Schafer R, Friedl P. 2002. Induction of protein aggregation in an early secretory compartment by elevation of expression level. Biotechnol Bioeng 78 (2): 131-140.
26. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. 2000. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2 (6): 326-332.
27. Lee GW. 2008. Stabilizing protein-folding conformations. Gen Eng Biotechnol News 28 (5): 60-63.
28. Lenny N, Green M. 1991. Regulation of endoplasmic reticulum stress proteins in COS cells transfected with immunoglobulin mu heavy chain cDNA. J Biol Chem 266 (30): 20532-20537.
29. Schlatter S, Stansfield SH, Dinnis DM, Racher AJ, Birch JR, James DC. 2005. On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechnol Prog 21 (1): 122-133.
30. Vanhove M, Usherwood YK, Hendershot LM. 2001. Unassembled Ig heavy chains do not cycle from BiP in vivo but require light chains to trigger their release. Immunity 15 (1): 105-114.
31. Lee CJ, Seth G, Tsukuda J, Hamilton RW. 2009. A clone screening method using mRNA levels to determine specific productivity and product quality for monoclonal antibodies. Biotechnol Bioeng 102 (4): 1107-1118.
32. Franco R, Daniela G, Fabrizio M, Ilaria G, Detlev H. 1999. Influence of osmolarity and pH increase to achieve a reduction of monoclonal antibodies aggregates in a production process. Cytotechnology 29 (1): 11-25.
33. Gomes JM, Hiller GW. 2008. Use of low temperature and/or low pH in cell culture. US Patent Application # US20080269132, Wyeth.
34. Freimuth P, Springer K, Berard C, Hainfeld J, Bewley M, Flanagan J. 1999. Coxsackievirus and adenovirus receptor amino-terminal immunoglobulin V-related domain binds adenovirus type 2 and fiber knob from adenovirus type 12. J Virol 73 (2): 1392-1398.
35. Chaderjian WB, Chin ET, Harris RJ, Etcheverry TM. 2005. Effect of copper sulfate on performance of a serum-free CHO cell culture process and the level of free thiol in the recombinant antibody expressed. Biotechnol Prog 21 (2): 550-553.
36. Gomes JM, Hiller GW, Luan Y-T, Wang W. 2008. Methods of protein production using anti-senescence compounds. US Patent Application # US20080274507, Wyeth.
37. Foster TM, Dormish JJ, Narahari U, Meyer JD, Vrkljan M, Henkin J, Porter WR, Staack H, Carpenter JF, Manning MC. 1996. Thermal stability of low molecular weight urokinase during heat treatment. III. Effect of salts, sugars and Tween 80. J Pharm 134 (1-2): 193-201.
38. Bondos SE, Bicknell A. 2003. Detection and prevention of protein aggregation before, during, and after purification. Anal Biochem 316 (2): 223-231.
39. Murphy KP. 2001. Stabilization of protein structure. Methods Mol Biol 168: 1-16.
40. Goldberg ME, Rudolph R, Jaenicke R. 1991. A kinetic study of the competition between renaturation and aggregation during the refolding of denatured-reduced egg white lysozyme. Biochemistry 30 (11): 2790-2797.
41. Hall CG, Abraham GN. 1984. Reversible self-association of a human myeloma protein. Thermodynamics and relevance to viscosity effects and solubility. Biochemistry 23 (22): 5123-5129.
42. Mire-Sluis A. 2008. Purification processes-Sorting out the good, the bad and the ugly. Presented at the Recovery of Biological Products XIII Conference, Philadelphia, PA, June.
43. Arakawa T, Timasheff SN. 1982. Stabilization of protein structure by sugars. Biochemistry 21 (25): 6536-6544.
44. Saluja A, Crampton S, Kras E, Fesinmeyer RM, Remmele RL Jr., Narhi LO, Brems DN, Gokarn YR. 2009. Anion binding mediated precipitation of a peptibody. Pharm Res 26 (1): 152-160.
45. Baldwin RL. 1996. How Hofmeister ion interactions affect protein stability. Biophys J 71 (4): 2056-2063.
46. Schein CH. 1990. Solubility as a function of protein structure and solvent components. Biotechnology 8 (4): 308-317.
47. Vrkljan M, Foster TM, Powers ME, Henkin J, Porter WR, Staack H, Carpenter JF, Manning MC. 1994. Thermal stability of low molecular weight urokinase during heat treatment. II. Effect of polymeric additives. Pharm Res 11 (7): 1004-1008.
48. Strambini GB, Gabellieri E. 1996. Proteins in frozen solutions-Evidence of ice-induced partial unfolding. Biophys J 70 (2): 971-976.
49. Kerwin BA, Heller M, Levin SH, Randolph TW. 1998. Effects of Tween 80 and sucrose on acute short-term stability and long-term storage at-20 degrees C of a recombinant hemoglobin. J Pharm Sci 87 (9): 1062-1068.
50. Watabe T, Ogura K, Satsukawa M, Okuda H, Hiratsuka A. 1994. Molecular cloning and functions of rat liver hydroxysteroid sulfotransferases catalysing covalent binding of carcinogenic polycyclic arylmethanols to DNA. Chem Biol Interact 92 (1-3): 87-105.
51. Porter WR, Staack H, Brandt K, Manning MC. 1993. Thermal stability of low molecular weight urokinase during heat treatment. I. Effects of protein concentration, pH and ionic strength. Thromb Res 71 (4): 265-279.
52. Gokarn Y, Fesinmeyer RM, Saluja A, Cao S, Dankberg J, Goetze A, Remmele RL Jr., Narhi LO, Brems DN. 2009. Ion specific modulation of protein interactions: Anion-induced, reversible oligomerization of a fusion protein. Protein Sci 18 (1): 169-179.
53. Hart RA, Smith SG, Shultz JE. 2005. Post-refolding harvest of E. coli expressed Fc-fusion proteins. Presented at the BioProcess International World Conference, Boston, September.
54. McCue JT, Engel P, Ng A, Macniven R, Thommes J. 2008. Modeling of protein monomer/aggregate purification and separation using hydrophobic interaction chromatography. Bioprocess Biosyst Eng 31 (3): 261-275.
55. Yigsaw Y. 2008. Improving upstream feed stock to downstream operations. Presented at the Recovery of Biological Products XIII, Quebec City, Quebec, Canada, June 22-27.
56. Clark EDB, Schwarz E, Rudolph R. 1999. Inhibition of aggregation side reactions during in vitro protein folding. Methods Enzymol 309: 217-236.
57. Clark EDB. 1998. Refolding of recombinant proteins. Curr Opin Biotechnol 9: 157-163.
58. Fink AL. 1998. Protein aggregation: Folding aggregates, inclusion bodies and amyloid. Fold Des 3: R9-R23.
59. St John RJ, Carpenter JF, Balny C, Randolph TW. 2001. High pressure refolding of recombinant human growth hormone from insoluble aggregates. Structural transformations, kinetic barriers, and energetics. J Biol Chem 276 (50): 46856-46863.
60. Bondos SE, Sligar S, Jonas J. 2000. High-pressure denaturation of apomyoglobin. Biochim Biophys Acta 1480 (1-2): 353-364.
61. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C Jr., Carpenter JF. 2009. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98: 94-104.
62. Amanullah A, McFarlane CM, Emery AN, Nienow AW. 2001. Scale-down model to simulate spatial pH variations in large-scale bioreactors. Biotechnol Bioeng 73 (5): 390-399.